| 77.20 Delayed Data As of Jan 18 |  -6.25 / -7.49%Today’s Change | 20.10 Today|||52-Week Range 300.00 | +9.44% Year-to-Date |
| Previous close | 83.45 |
| Today’s open | 84.90 |
| Day’s range | 75.00 - 86.43 |
| Volume | 5,950,177 |
| Average volume (3 months) | 5,461,361 |
| Market cap | $10.2B |
| Earnings growth (last year) | +2.44% |
| Earnings growth (this year) | -- |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | +62.43% |
| P/E ratio | NM |
| Price/Sales | -- |
| Price/Book | -- |
| Today’s change | Today’s % change | |
|---|---|---|
| NBIXNeurocrine Bioscienc... | +2.93 | +3.31% |
| EXASExact Sciences Corp | +3.17 | +4.19% |
| BLUEbluebird bio Inc | +3.46 | +2.74% |
| NKTRNektar Therapeutics | +0.78 | +1.72% |
| Next reporting date | February 27, 2019 |
| EPS forecast (this quarter) | -$0.11 |
| Annual revenue (last year) | $20.5M |
| Annual profit (last year) | -$7.8M |
| Net profit margin | -38.02% |
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Brendan Kennedy |
Chief Financial Officer, Secretary & Treasurer Mark Castaneda |
Corporate headquarters Nanaimo, British Columbia |
